

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Down syndrome	Serotonin (5-HT) transporter (SLC6A4; SERT)	<p>Mouse studies suggest that a selective serotonin reuptake inhibitor (SSRI) could help treat cognitive impairment associated with Down syndrome. In a mouse model of Down syndrome, delivery of Prozac fluoxetine on postnatal days 3–15 increased neuronal proliferation to levels that were similar to those in wild-type controls. The Prozac-treated mice also had memory performance similar to that of wild-type mice in a contextual fear conditioning test. Next steps include clinical testing in children with Down syndrome.</p> <p>Eli Lilly and Co. markets Prozac fluoxetine to treat depression, premenstrual syndrome (PMS) and cachexia.</p> <p><b>SciBX 3(27); doi:10.1038/scibx.2010.835</b> Published online July 15, 2010</p>	Findings unpatented; unavailable for licensing	<p>Bianchi, P. <i>et al. J. Neurosci.</i>; published online June 30, 2010; doi:10.1523/JNEUROSCI.0534-10.2010</p> <p><b>Contact:</b> Renata Bartesaghi, University of Bologna, Bologna, Italy e-mail: <a href="mailto:renata.bartesaghi@unibo.it">renata.bartesaghi@unibo.it</a></p>